三七通舒胶囊治疗病毒性脑炎的临床研究

目的：观察三七通舒胶囊治疗病毒性脑炎的临床疗效。方法：随机、开放、对照试验。85例年龄在14—59岁的病毒性脑炎患者随机分为三七通舒胶囊早期治疗组（A治疗组，27例）、三七通舒胶囊延迟治疗组（B治疗组，30例）和对照组（28例）。A治疗组在常规治疗的基础上立即口服三七通舒胶囊0．2gTid，共3月，B治疗组在常规治疗5天后加用三七通舒胶囊0．2gTid，共3月。观察三组患者的急性期症状、体征消失时间，3月后用90项症状清单（SCL-90）、简易智力筛查量表（MMSE）及神经功能缺损评分（ESS）评价患者的远期疗效。结果：A治疗组急性期症状（发热、头痛呕吐、惊厥及意识障碍）的改善均明显优于B治疗组和对照组（P〈0．05或P〈0．01），而B治疗组与对照组比较无统计学差异（P〉0．05）。治疗后3月，两治疗组的SCL-90、MMSE及ESS评分均好于对照组（P〈0．05或P〈0．01），同时A治疗组的SCL-90、MMSE评分好于B治疗组（P〈0．05）。结论：三七通舒胶囊治疗病毒性脑炎能减轻急性期症状，改善远期预后；早期使用三七通舒胶囊可取得更好的效果。

Treatment by Using Sanqitongshujiaonang for Patients with Viral Ence Phalitis: Results of a Randomized,Open-labeled,Controlled Clinical Trial

Objective： To evaluate the clinical efficacy of Sanqitongshujiaonang in treating patients with viral encephalitis. Methods： A randomized, open -labeled, controlled clinical trial was conducted. In this trail, 85 patients with viral encephalitis, aged 14- 59 years, were enrolled. They were assigned to three groups randomLy, 27 in early treatment group with Sanqitongshujiaonang （ treatment group A） , 30 in later treatment group with Sanqitongshujiaonang （treatment group B）, and 28 in control group. Besides, the two trial groups were treated with Sanqitongshujiacnang （0. 2 rid, for 3 months） at the very beginning of conventional therapy and 5 days later after treated with conventional therapy respectively, while the control group was treated with conventional therapy only. Compared the disappearance time of clinical symptoms and signs at the acute stage and the scores of SCL - 90, MMSE and ESS 3 months later group to group. Results： Treatment group A was better than beth treatment group B and control group （P 〈 0. 05 or P 〈 0. 01 ）, while the difference between treatment group B and control group was not significant （ P 〉 0. 05 ） in improving the acute symptoms and signs. Both the two trial groups＇ scores of SCL - 90, MMSE and ESS 3 months later after treatment were better than the control group＇ （ P 〈 0.05 or P 〈 0. 01 ）, and treatment group A＇ s scores of SCL - 90, MMSE were better than treatment group B （ P 〈 0. 05） . Conclusion： Sanqitongshujiaonang can improve the acute symptoms and the long - term prognosis of the patients with viral encephalitis, and the earlier usage of it can get better effects.